Biotech Archives - Page 681 of 795

3 minute read

September 28, 5:45 PM

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis are most in need of

REGN

2 minute read

Atara Biotherapeutics To Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel Commercialization Agreement With Pierre Fabre; Atara To Receive Additional $30M Upon European Commission Approval And Filing Of Tab-Cel

By Benzinga Newsdesk

September 28, 4:03 PM

Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel® Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines

ATRA

2 minute read

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer’s Data

By Joel Elconin

September 28, 2:53 PM

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have instigated wild price gyrations in the issue.

BIIB

3 minute read

Cyclo Therapeutics On Track To Commence Enrollment & Dosing Of Phase 2 Study Of Trappsol Cyclo For Treatment Of Alzheimer’s Disease Before Year End

By Benzinga Newsdesk

September 28, 2:08 PM

– Company on track to commence enrollment and dosing of Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer's disease before year end – Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1)

CYTH

1 minute read

PepGen’s Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta’s Candidate, Says Analyst

By Vandana Singh

September 28, 1:59 PM

PepGen Inc (NASDAQ:PEPG) reported data from PGN-EDO51’s SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes…

PEPG

1 minute read

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders

By Vandana Singh

September 28, 12:39 PM

MaxCyte Inc (NASDAQ: MXCT) has signed a

CRSP

1 minute read

Rallybio’s Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets

By Vandana Singh

September 28, 12:37 PM

Rallybio Corporation (NASDAQ:RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune…

RLYB

1 minute read

KemPharm’s Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder

By Vandana Singh

September 28, 12:07 PM

KemPharm Inc (NASDAQ:KMPH) announced topline data from its exploratory Phase 1 trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate…

KMPH

2 minute read

Immunovant Announces IMVT-1402, A Next Generation Anti-FcRn; Plan To Submit IND And Initiate Phase 1 Study In Early 2023 With Initial Data Expected In Mid-2023.

By Benzinga Newsdesk

September 28, 10:47 AM

In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023

IMVT

1 minute read

OraSure Secures BARDA Funding For Next-Gen Ebola Diagnostic Test

By Vandana Singh

September 28, 10:28 AM

The Biomedical Advanced Research and Development Authority (BARDA) has issued an $8.6 million contract to OraSure Technologies Inc (NASDAQ:OSUR) for developing a…

OSUR